The main market opportunities involve providing training and solutions for regulatory compliance and V&V best practices in regulated industries. This includes developing Master Validation Plans, ...

The life science industry faces opportunities in enhancing cGMP compliance by developing robust, risk-based Validation and Verification strategies. Training on creating effective Master Validation ...

Expert insights on QMSR compliance: transition steps, gap assessments, risk-based approach, and global harmonization with ISO ...

The US Food and Drug Administration (FDA) recently issued three warning letters to facilities in China, the US, and India for ...

An overview of the validation and qualification requirements introduced in the 2022 EU GMP Annex 1 revision, with a focus on ...

Boston Cell Standards enters into final phase of US FDA’s MDDT programme to qualify first-in-industry to standardize cancer diagnostic assays: Boston Wednesday, April 29, 2026, ...

Over the past year, we have carefully considered whether — and how — life sciences companies can use AI tools in their clinical development ...

The pair will develop drug-digital therapeutic combinations as a singular product, thus sidestepping reimbursement hurdles linked to individually approved digital therapies.

Discover how quality-driven drug development and AI accelerate safer medicines, reduce risk, and improve patient outcomes.

Converge Bio, the Generative AI Lab for the Life Sciences, shares findings from a new study showing that ConvergeABtm, their antibody design and optimization solution, was able to improve cetuximab, a ...

Remepy, the pioneer of Hybrid Drugs, today announced a collaboration with Merck KGaA, Darmstadt Germany, a leading science and technology company, to explore the development of Hybrid Drugs across ...

Closed vs modular automation defines how high-throughput screening laboratories balance efficiency and flexibility. Closed ...